论文部分内容阅读
目的：探讨胰腺癌组织基质质属蛋白酶２（ ＭＭＰ２） 和基质金属蛋白酶抑制剂２（ＴＩＭＰ２） 表达与肿瘤侵袭转移和预后的关系。方法： 通过免疫组化方法检测３５ 例胰腺癌病理标本和１０ 正常胰腺标本ＭＭＰ２ 和ＴＩＭＰ２ 的半定量表达情况及其与肿瘤临床病理参数和预后的关系，生存分析采用Ｋａｐｌａｎｍｅｉｅｒ 方法。结果：胰腺癌ＭＭＰ２ 和ＴＩＭＰ２ 表达阳性率明显高于正常对照组， 与淋巴结转移和临床分级密切相关， 但与胰腺癌的分化程度无关，Ｋａｐｌａｎｍｅｉｅｒ 分析发现ＭＭＰ２ 和ＴＩＭＰ２ 高表达患者的生存时间明显低于ＭＭＰ２ 和ＴＩＭＰ２ 低表达患者（ Ｐ＜０－００１） 。结论：胰腺癌ＭＭＰ２ 和ＴＩＭＰ２ 表达与肿瘤侵袭转移和预后密切相关，有助于确定术后治疗方案。
Objective: To investigate the relationship between the expression of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase inhibitor-2 (TIMP-2) and the invasion, metastasis and prognosis of pancreatic cancer. Methods: Immunohistochemistry was used to detect the semi-quantitative expression of MMP 2 and TIMP 2 in 35 specimens of pancreatic cancer and 10 normal pancreatic specimens and their relationship with clinicopathological parameters and prognosis. KaplanMeier method was used for survival analysis. . Results: The positive rate of MMP-2 and TIMP-2 expression in pancreatic cancer was significantly higher than that in the normal control group. It was closely related to lymph node metastasis and clinical grade. However, it was not related to the degree of pancreatic cancer differentiation. Kaplan-meier analysis found that MMP-2 and TIMP-II 2 The survival time of patients with high expression was significantly lower than those with low expression of MMP-2 and TIMP-2 (P<0-001). Conclusion: The expression of MMP 2 and TIMP 2 in pancreatic cancer is closely related to the invasion, metastasis and prognosis of the tumor, and it is helpful to determine the treatment plan.